

# Simple Enantiospecific Syntheses of the C(2)-Diastereomers of Omuralide and 3-Methylomuralide


Leleti Rajender Reddy, P. Saravanan, Jean-François Fournier,  
B. V. Subba Reddy, and E. J. Corey\*

Department of Chemistry and Chemical Biology, Harvard University,  
12 Oxford Street, Cambridge, Massachusetts 02138

corey@chemistry.harvard.edu

Received April 20, 2005


## ABSTRACT



Syntheses of two novel omuralide derivatives are described.

Omuralide (**1**) is a highly selective and potent covalent inhibitor of the proteasome, the cylindrical multiprotein assembly that degrades polyubiquitinated proteins.<sup>1,2</sup> The proteasome functions to remove damaged or misfolded proteins and to play a major role in maintaining optimum levels of individual proteins in cells and tissues. This role is especially important for regulatory proteins such as those involved in signaling, cell-cycle control, DNA repair, transcription, and apoptosis.<sup>2</sup> As a result of previous synthetic work in these laboratories, we were able to develop a clear structure–activity correlation for a considerable number of omuralide analogues.<sup>1a</sup> One interesting finding was that 2-methylomuralide<sup>3,4</sup> (**2**) retained most of the potency of **1**.<sup>1a</sup> This fact prompted us to develop a synthesis of 2-epi-

omuralide (**3**) for evaluation of its activity in proteasome inhibition, especially because of the availability in our laboratory of advanced intermediates for the synthesis, specifically the ester–aldehyde **4** (see Scheme 1). This chiral ester aldehyde can be prepared in quantity from methyl 4-methyl-2-pentenoate by the use of catalytic enantioselective methodology.<sup>4</sup>




Reaction of **4** with 2 equiv of the *E*-*tert*-butyldimethylsilyl enol ether of methyl propionate in THF (from LDA and methyl propionate in THF at  $-78^{\circ}\text{C}$ ) and 1.1 equiv of powdered  $\text{LiClO}_4$  (moisture-containing, but not dry) in  $\text{CH}_2\text{Cl}_2$  at  $-78^{\circ}\text{C}$  for 20 h gave as major product the *syn* aldol adduct **5**. Acid-catalyzed methanolysis of crude **5** with refluxing methanolic HCl and concomitant lactamization provided the pure  $\gamma$ -lactam benzoate **6** (63% overall from **4**) after flash chromatography on silica gel. Saponification of the benzoate-methyl ester **6** provided the dihydroxy acid

(1) (a) Reviewed in: Corey, E. J.; Li, W.-D. *Z. Chem. Pharm. Bull.* **1999**, *47*, 1–10. (b) Corey, E. J.; Reichard, G. A.; Kania, R. *Tetrahedron Lett.* **1993**, *34*, 6977–6980. (c) Corey, E. J.; Reichard, G. A. *J. Am. Chem. Soc.* **1992**, *114*, 10677–10678. (d) Fenteany, G.; Standaert, R. F.; Reichard, G. A.; Corey, E. J.; Schreiber, S. L. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 3358–3362.


(2) (a) Hershko, A. *Le Prix Nobel*; Nobel Foundation: Stockholm, 2005. (b) <http://nobelprize.org/chemistry/laureates/2004/public.html>. (c) De Martino, G. N.; Slaughter, C. A. *J. Biol. Chem.* **1999**, *274*, 22123–22126. (d) Glickman, M. H.; Liechmanover, A. *Physiol. Rev.* **2001**, *82*, 373–428. (e) Tansey, N. P. *New Engl. J. Med.* **2004**, *351*, 393–394. (f) Ehlers, M. D. *Nature Neurosci.* **2003**, *6*, 231–242. (g) Adams, J. *Proteasome Inhibitors in Cancer Therapy*; Humana Press: New York, 2004.

(3) Corey, E. J.; Li, W.-D. *Z. Tetrahedron Lett.* **1998**, *39*, 7475–7478.

(4) Saravanan, P.; Corey, E. J. *J. Org. Chem.* **2003**, *68*, 2760–2764.




7. Reaction of **7** with bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOPCl) and Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> at 23 °C for 1 h gave, after extractive isolation (EtOAc) and flash chromatography on silica gel, the desired  $\beta$ -lactone **3**, mp 170–172 °C.<sup>5</sup> The structure of **3** was confirmed by single-crystal X-ray diffraction analysis (Figure 1).



**Figure 1.** ORTEP presentation of **3**.

A key step in the synthesis of **3** that is outlined in Scheme 1 is the doubly diastereoselective Mukaiyama aldol coupling **4**  $\rightarrow$  **5**. The preparation of the very sensitive aldehyde **4** was accomplished by addition of a  $-78$  °C solution of the Swern

(5) Physical data for **3**: *R*<sub>f</sub> 0.50 (neat EtOAc); [ $\alpha$ ]<sub>D</sub><sup>23</sup>  $-70.1$  (*c* 1.0, MeCN); FTIR (film)  $\nu_{\text{max}}$  3456, 2948, 1835, 1719, 1648, 1510, 1250, cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)  $\delta$  7.0 (1H, br s,  $-NH$ ), 4.86 (1H, s), 3.75 (1H, dd, *J* = 13.2, 6.0 Hz), 3.58 (1H, d, *J* = 7.2 Hz), 2.70 (1H, q, *J* = 7.8 Hz), 1.78 (1H, m), 1.24 (3H, d, *J* = 8.4 Hz), 0.99 (3H, d, *J* = 6.9 Hz), 0.90 (3H, d, *J* = 6.8 Hz).



reagent formed from DMSO and ClCOCOC<sub>2</sub>H<sub>5</sub> in CH<sub>2</sub>Cl<sub>2</sub> to the primary alcohol precursor and Et<sub>3</sub>N at  $-78$  °C,<sup>4</sup> addition of pentane to the reaction product, filtration, and evaporation in vacuo (95% yield). It was crucial to use a nonaqueous workup since **4** rapidly undergoes retroaldol cleavage under aqueous conditions. Pure **4** could be stored unchanged at  $-78$  °C for at least 1 day. The optimum catalyst for the transformation **4**  $\rightarrow$  **5** was found to be LiClO<sub>4</sub> (not rigorously dried and containing a small amount ( $>2\%$ ) of moisture). One straightforward explanation for the observed syn aldol diastereoselectivity is outlined in Scheme 2. In this sequence, the formyl and COOMe carbonyl oxygens of **4** coordinate with LiClO<sub>4</sub> to form a chelated intermediate which then couples with the enol silyl ether as shown in Scheme 2 to generate the *syn* aldol adducts. This pathway to the *syn* product **5** appears to be favored over alternative pre-transition-state assemblies because it involves a minimum of steric repulsion.

We have also taken advantage of the availability of an advanced intermediate (**10**) for the synthesis of other omuralide derivatives<sup>6</sup> to prepare 3-methyl-2-*epi*-omuralide (**8**), a hybrid of **3**, and salinosporamide A (**9**) (Scheme 3), for which we have described three different routes.<sup>6,7,8</sup> The keto acrylamide **10**<sup>6,7</sup> was added to the Kulinkovich reagent<sup>9</sup> (3.5 equiv) formed by treatment of 4 equiv of Ti(*i*-PrO)<sub>4</sub> with 7 equiv of cyclopentylmagnesium chloride in *t*-BuOMe at  $-40$  °C for 30 min and then allowed to react at  $-40$  °C for another 1 h and at  $-20$  °C for 20 h. The cyclized titanium-containing intermediate thus formed (see below) was then quenched with excess 1 *N* hydrochloric acid. Extractive isolation afforded a single diastereomeric  $\gamma$ -lactam, **11**, which was isolated in 95% yield after flash chromatography on silica gel.<sup>10,11</sup> The TBS ether protecting group of **11** was cleaved using 1:1 48% aq HF in acetonitrile to form the

(6) Reddy, L. R.; Fournier, J.-F.; Subba Reddy, B. V.; Corey, E. J. *J. Am. Chem. Soc.*, published online June 2, 2005 <http://dx.doi.org/10.1021/ja052376o>.


(7) Reddy, L. R.; Fournier, J.-F.; Subba Reddy, B. V.; Corey, E. J. *Org. Lett.* **2005**, *7*, 2699–2702.

(8) Reddy, L. R.; Saravanan, P.; Corey, E. J. *J. Am. Chem. Soc.* **2004**, *126*, 6230–6231.

(9) For reviews on the application of titanacyclopropane reagents, see: (a) Kulinkovich, O. G. *Chem. Rev.* **2003**, *103*, 2597–2632. (b) Sato, F.; Okamoto, S. *Adv. Synth. Catal.* **2001**, *343*, 759–784.

(10) For the closest precedent to this cyclization involving  $\delta,\epsilon$ -enones, see: (a) Kablaoui, N. M.; Buchwald, S. L. *J. Am. Chem. Soc.* **1996**, *118*, 3182–3191. (b) Mandal, S. K.; Amin, S. R.; Crowe, W. E. *J. Am. Chem. Soc.* **2001**, *123*, 6457–6458. (c) Crowe, W. E.; Vu, A. T. *J. Am. Chem. Soc.* **1996**, *118*, 1557–1558. (d) Quan, L. G.; Cha, J. K. *Tetrahedron Lett.* **2001**, *42*, 8567–8569.

Scheme 3




dihydroxy ester **12**,<sup>12</sup> further transformed into **13** by oxidative cleavage of the *N*-*p*-methoxybenzyl protecting group.<sup>13</sup> Saponification of methyl ester **13** followed by lactonization of the resulting dihydroxy acid yielded 3-methyl-2-*epi*-omuralide **8** as a colorless solid<sup>14</sup> that was distinctly different from a sample of 3-methylomuralide.<sup>7</sup>

The relative stereochemistry of the titanacyclopentene-mediated cyclization **10** → **11** about carbons 3 and 4 follows unambiguously from the formation of the  $\beta$ -lactone ring.

(11) Characterization data for **11**:  $R_f$  0.40 (hexanes–EtOAc 50:50); mp 43–44 °C;  $[\alpha]_D^{25} +10.4$  (*c* 2.5, CHCl<sub>3</sub>); FTIR (film)  $\nu_{\max}$  3386, 2954, 2935, 1748, 1683, 1515, 1245, 1177, 1055, 835 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz)  $\delta$  7.09 (2H, d, *J* = 8.8 Hz), 6.81 (2H, d, *J* = 8.8 Hz), 4.88 (1H, d, *J* = 15.5 Hz), 4.54 (1H, d, *J* = 16 Hz), 4.13 (1H, d, *J* = 0.8 Hz), 4.04 (1H, s), 3.76 (3H, s), 3.49 (3H, s), 2.59 (1H, m), 2.41 (1H, q, *J* = 7.6 Hz), 1.41 (3H, s), 1.17 (3H, d, *J* = 7.6 Hz), 1.09 (3H, d, *J* = 7.2 Hz), 0.94 (9H, s), 0.90 (3H, d, *J* = 6.4 Hz), 0.17 (3H, s), -0.05 (3H, s); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  176.62, 173.18, 158.31, 130.95, 127.58, 113.98, 80.77, 79.78, 77.58, 55.44, 52.47, 48.40, 47.28, 28.80, 26.62, 24.34, 20.05, 19.11, 16.01, 10.37, -1.51, -4.08; HRMS (ESI) *m/z* calcd for C<sub>26</sub>H<sub>44</sub>NO<sub>6</sub>Si [*M* + *H*<sup>+</sup>] 494.2938, found 494.2932.

(12) Characterization data for **12**: colorless solid;  $R_f$  0.60 (EtOAc); mp 126–128 °C  $[\alpha]_D^{25} +22.0$  (*c* 0.3, CHCl<sub>3</sub>); FTIR (film)  $\nu_{\max}$  3392, 2952, 2912, 1752, 1673, 1515, 1246, 1177, 1036, 835 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600 MHz)  $\delta$  7.32 (2H, d, *J* = 8.4 Hz), 6.85 (2H, d, *J* = 9.0 Hz), 4.75 (2H, d, *J* = 6.6 Hz), 3.80 (3H, s), 3.70 (3H, s), 3.65 (1H, d, *J* = 5.5 Hz), 2.63 (1H, q, *J* = 7.2 Hz), 2.15 (1H, m), 1.32 (3H, s), 1.24 (3H, d, *J* = 7.2 Hz), 0.92 (3H, d, *J* = 7.2 Hz), 0.87 (3H, d, *J* = 6.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  177.36, 172.44, 158.62, 131.24, 128.87, 113.90, 80.33, 77.54, 55.45, 52.48, 48.85, 46.27, 30.40, 21.48, 18.86, 17.86, 10.15; HRMS (ESI) *m/z* calcd for C<sub>20</sub>H<sub>30</sub>NO<sub>6</sub> [*M* + *H*<sup>+</sup>] 380.2028, found 380.2024.

Since the absolute configurations at carbons 4 and 5 have been established unambiguously by previous work<sup>6,7</sup> and since the absolute configuration at carbon 2 is now also clear, there is no doubt about the overall correctness of the transformation **10** → **11**. The *trans* relationship of the methyl substituent at C(2) and the hydroxyl group at C(3) of **11** contrasts with previous work on the Ti-mediated cyclization of  $\delta,\epsilon$ -unsaturated ketones<sup>10</sup> and is thus surprising. This observed *trans* arrangement of substituents at C(2) and C(3) indicates that the cyclization occurs not through a bicyclic organotitanium intermediate such as **14**, but via a monocyclic structure such as **15**. The formation of intermediate **15** may



occur by a pathway such as the following: (1) transfer of (RO)<sub>2</sub>Ti from the Kulinkovich complex with cyclopentene to the acrylamide  $\alpha,\beta$ -double bond of **10** and (2) radical addition of that intermediate to a chelate of MgCl<sup>+</sup> with the COOMe and CH<sub>3</sub>CO carbonyl oxygens of the complex from **10** to effect cyclization to **15**. Proteolysis of **15** obviously leads to the observed product **11**. Regardless of the mechanistic pathway for the formation of **11** from **10**, it seems likely that Kulinkovich complex induced cyclizations have even greater synthetic potential than previously realized.

In summary, the omuralide analogues **3** and **8** are now available by efficient and practical stereocontrolled routes.

**Acknowledgment.** J.-F.F. is grateful to NSERC of Canada for a postdoctoral fellowship.

**Supporting Information Available:** Complete data for the X-ray crystal structure of **3** are given. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL050874W

(13) Characterization data for **13**: colorless solid;  $R_f$  = 0.2 (EtOAc); mp ~180 °C dec;  $[\alpha]_D^{25} -2.6$  (*c* 1.5, MeOH); FTIR (film)  $\nu_{\max}$  3325, 2956, 2925, 1725, 1683, 1252, 1167, 1096, 1021, 835 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD, 600 MHz)  $\delta$  5.49 (1H, s, NH), 3.80 (1H, d, *J* = 4.8 Hz), 3.73 (3H, s), 2.35 (1H, q, *J* = 7.8 Hz), 1.63 (1H, m), 1.49 (3H, s), 1.26 (3H, d, *J* = 7.8 Hz), 0.94 (3H, d, *J* = 7.2 Hz), 0.90 (3H, d, *J* = 6.6 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz)  $\delta$  181.41, 171.33, 80.48, 78.96, 74.60, 51.23, 50.97, 31.33, 20.28, 18.51, 16.98, 11.53; HRMS (ESI) *m/z* calcd for C<sub>12</sub>H<sub>22</sub>NO<sub>5</sub> [*M* + *H*<sup>+</sup>] 260.1498, found 260.1495.

(14) Characterization data for **8**:  $R_f$  = 0.53 (EtOAc); mp 145–147 °C;  $[\alpha]_D^{25} -12.2$  (*c* 0.6, CHCl<sub>3</sub>); FTIR (film)  $\nu_{\max}$  3355, 2966, 2927, 1825, 1704, 1345, 1048, 850 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  6.63 (1H, br), 3.75 (1H, d, *J* = 7.0 Hz), 2.79 (1H, q, *J* = 8.0 Hz), 1.92 (1H, m), 1.69 (3H, s), 1.24 (3H, d, *J* = 6.0 Hz), 1.12 (3H, d, *J* = 7.5 Hz), 1.08 (1H, d, *J* = 6.5 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  179.03, 169.91, 87.00, 79.59, 71.51, 44.36, 31.48, 19.87, 18.69, 16.84, 13.09; HRMS (ESI) calcd for C<sub>11</sub>H<sub>21</sub>IN<sub>2</sub>O<sub>4</sub> [*M* + NH<sub>4</sub>]<sup>+</sup> 245.1501, found 245.1491.